Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 8/20 | 0.47 |
| ▸ | RAB9A | P51151 | 8/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.47 |
| ▸ | RELA | Q04206 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 6/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | GMNN | O75496 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15249331 | 0.94 | NPC1 (0.45) | ARNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL8739602 | 0.86 | AR (0.58) | ARNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL15249330 | 0.80 | AR (0.51) | ARNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL61467 | 0.76 | NPC1 (0.56) | ARNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL11807152 | 0.75 | ALDH1A1 (0.42) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL8738496 | 0.74 | NPC1 (0.50) | ARNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL18216986 | 0.73 | MEN1 (0.42) | RAB9AKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL12970039 | 0.73 | MEN1 (0.42) | RAB9AKDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL12112870 | 0.72 | RAB9A (0.80) | ARNPC1RAB9AKDM4ESMN1; SMN2 | |
| SCHEMBL4972628 | 0.72 | ALDH1A1 (0.39) | KDM4EALDH1A1MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040021-B2 | Heterocyclic compounds as imaging probes of tau pathology | GE HEALTHCARE LIMITED (GB) | 2015-05-26 | — | — | US | disclosed |
| US-9040021-B2 | Heterocyclic compounds as imaging probes of tau pathology | GE HEALTHCARE LIMITED (GB) | 2015-05-26 | — | — | US | disclosed |
| US-20130236395-A1 | HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY | GE HEALTHCARE LIMITED (GB) | 2013-09-12 | — | — | US | disclosed |
| US-20130236395-A1 | HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY | GE HEALTHCARE LIMITED (GB) | 2013-09-12 | — | — | US | disclosed |
| WO-2012067863-A1 | HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY | GE HEALTHCARE LIMITED (GB) | 2012-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130236395-A1 | HETEROCYCLIC COMPOUNDS AS IMAGING PROBES OF TAU PATHOLOGY | MAPT, PSEN1, PSEN2 | AR 3587/4885NPC1 127/4885RAB9A 1703/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.